Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. What are the survival rates for melanoma skin cancer, by stage? 2015. Available from http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates. Accessed December 30, 2016.
   Google Scholar
• Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v126–v32.
   PubMed Web of Science ®Google Scholar
• Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol. 2011;131:1817–20.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Flaherty KT. New strategies in melanoma: Entering the era of combinatorial therapy. Clin Cancer Res. 2015;21:2424–35.
   PubMed Web of Science ®Google Scholar
• Mai R, Zhou S, Zhong W, et al. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget. 2015;6:28502–12.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S, Cochrane handbook for systematic reviews of interventions. Chichester (UK): Wiley Online Library. 2008.
   Google Scholar
• Scottish Intercollegiate Guidelines Network. METHODOLOGY CHECKLIST 3: COHORT STUDIES (Version 3.0). Available from http://www.sign.ac.uk/methodology/checklists.html. Accessed December 30, 2016.
   Google Scholar
• Daud A, Weber JS, Sosman JA, et al. Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). J Clin Oncol. 2015;33:9036.
   Web of Science ®Google Scholar
• Flaherty K, Daud A, Weber JS, et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D + T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). J Clin Oncol 2014;32:9010.
   Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–703.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.
   PubMed Web of Science ®Google Scholar
• Larkin JMG, Yan Y, McArthur GA, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol. 2015;33:9006.
   Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Wilmott JS, Drummond M, et al. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer. 2015;121:3826–35.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib. N Engl J Med. 2012;366:707–14.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–72.
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207–15.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.
   PubMed Web of Science ®Google Scholar
• Yushak M, Kluger HM, Sznol M. Advances in the systemic treatment of metastatic melanoma. Oncology. 2013;27:374–81.
   PubMed Web of Science ®Google Scholar
• Wargo JA, Lawrence DP, Cooper ZA, et al. A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma. J Clin Oncol. 2015;33:e20074.
   Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Phase i trial evaluating concurrent vemurafenib and ipilimumab in patients with advanced BRAF-mutant melanoma. Eur J Cancer 2013;49:S867.
   Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W-65–-94.
   Web of Science ®Google Scholar